{"organizations": [], "uuid": "145f6eabc5a8c9ea7b14ce9910967e12b7363d0b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-voyager-therapeutics-rpeorts-q1-ga/brief-voyager-therapeutics-rpeorts-q1-gaap-loss-per-share-of-0-63-idUSASC0A1DJ", "country": "US", "domain_rank": 408, "title": "Voyager Therapeutics Rpeorts Q1 GAAP Loss Per Share Of $0.63", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-10T19:13:00.000+03:00", "replies_count": 0, "uuid": "145f6eabc5a8c9ea7b14ce9910967e12b7363d0b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-voyager-therapeutics-rpeorts-q1-ga/brief-voyager-therapeutics-rpeorts-q1-gaap-loss-per-share-of-0-63-idUSASC0A1DJ", "ord_in_thread": 0, "title": "Voyager Therapeutics Rpeorts Q1 GAAP Loss Per Share Of $0.63", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "voyager therapeutics inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " Updated 8 minutes ago BRIEF-Voyager Therapeutics Rpeorts Q1 GAAP Loss Per Share Of $0.63 Voyager Therapeutics Inc:\n* VOYAGER THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS * Q1 GAAP LOSS PER SHARE $0.63\n* Q1 EARNINGS PER SHARE VIEW $-0.11 â€” THOMSON REUTERS I/B/E/S\n* CASH, CASH EQUIVALENTS, AND MARKETABLE DEBT SECURITIES AS OF MARCH 31, 2018 WERE $218.2 MILLION\n* VOYAGER THERAPEUTICS - CONTINUES TO EXPECT TO END 2018 WITH TOTAL CASH, CASH EQUIVALENTS, MARKETABLE DEBT SECURITIES OF ABOUT $125 MILLION TO $135 MILLION\n* VOYAGER THERAPEUTICS - PROJECTS TO CURRENTLY BE ABLE TO FUND OPERATING EXPENSES, CAPEX REQUIREMENTS INTO EARLY 2020 ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-10T19:13:00.000+03:00", "crawled": "2018-05-10T14:25:25.004+03:00", "highlightTitle": ""}